LAMH (Laboratory for Advanced Medicine & Health Group) is a pioneering company dedicated to AI-driven early cancer screening and diagnosis. Co-founded by international business leaders, top scientists, and renowned doctors, LAMH adheres to the principle of "making cancer screening earlier, more precise, more accessible, and more user-friendly." LAMH is the first and only global company that carries out R&D, production, approval, lab testing, and commercialization of early cancer screening and diagnostic technologies in both China and the United States, the world's two largest economies.

LAMH introduced its inaugural early liver cancer detection product, IvyGene, in China, offering timely, accurate, accessible, and simplified liver cancer screening and diagnostic solutions. This innovation has transformed the clinical screening, diagnosis, and monitoring pathways for liver cancer, addressing unmet clinical and health needs in both China and the United States through value-based healthcare.

LAMH is committed to the methylation approach, utilizing early cancer screening biomarkers such as miRNA, gene mutations, and methylation. The company has independently developed and patented numerous innovations, including MESA, which integrates methylation, nucleosome, and fragment group detection technology, CHALM bioinformatics algorithms, and 66 international PCT and Chinese-American patents that encompass 22 cancer types and 3000+ biomarker detection technologies and bioinformatics algorithms.